German watchdog deals another setback to Bayer eye drug Eylea
December 15, 2014 at 09:06 AM EST
FRANKFURT, Dec 15 (Reuters) - Bayer's eye medication Eylea does not offer an advantage over a rival product from Novartis when treating patients with a type of diabetes-related swelling of the retina, a German healthcare cost watchdog said on Monday.
